Regorafenib monotherapy in pretreated metastatic colorectal cancer (CORRECT): an international, multicenter, randomized, placebo-controlled clinical trial Phase 3
2013
Abstract
Patients with metastatic colorectal car- CaP are usually treated with chemotherapy based fluoropyrimidine, oxaliplatin, irinotecan and antiangiogením antibody bevacizumab (anti-VEGF - vascular endothelial Growth Factor). In patients with KRAS nemutova- described type of tumors can be further treated through tilátkami - cetuximab or panitumumab, which are directed against the EGFR (epidermal growth factor receptor).
In the pathogenesis of progression colorectal cancer plays an important role activation of various kinases (EGFR, VEGFR, PDGFR, FGFR) and down-regulation of signaling cascades RAS-RAF-MEK-ERK and PI3K-PTEN-AKT-mTOR.1)